ZVRA (Zevra Therapeutics) GF Value : $9.02 (As of Mar. 24, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics GF Value?

As of today (2025-03-24), Zevra Therapeutics's share price is $7.99. Zevra Therapeutics's GF Value is $9.02. Therefore, Zevra Therapeutics's Price-to-GF-Value for today is 0.89. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Zevra Therapeutics is Modestly Undervalued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Zevra Therapeutics (NAS:ZVRA) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Zevra Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	7.99	/	9.02
	=	0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zevra Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Zevra Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (NAS:ZVRA) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

1GDA:Germany

Address

1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747

Website

https://www.zevra.com

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Executives

Neil F. Mcfarlane	director, officer: President and CEO	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
R. Laduane Clifton	officer: VP Fin & Corp Controller	C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747
Joshua Schafer	officer: CCO & EVP, Bus. Development	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Timothy J. Sangiovanni	officer: VP, Corporate Controller	C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241
Watton Corey Michael	director	22045 KAREN STREET, ELKHORN NE 68022
Thomas Anderson	director	215 FIRST STREET, CAMBRIDGE MA 02142
John B Bode	director	C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012
Douglas W Calder	director	324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Wendy L Dixon	director
Tamara A Seymour	director	C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Matthew R Plooster	director	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard W Pascoe	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Christopher Posner	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Travis C Mickle	director, 10 percent owner, officer: President & CEO	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241